AURA

6.8701.58%
GM

Giovanni Mariggi

Independent Director

Mr. Giovanni Mariggi is Chairman of the Board of Vaderis Therapeutics AG. Mr. Mariggi is Member of Advisory Board of Breakpoint Therapeutics GmbH. Mr. Mariggi is Director of Fore Biotherapeutics Inc. from August 2023. He has B.S. in Biochemistry from Imperial College London Ltd. He has Ph.D. in Biochemistry, Molecular Biology from University College London. He has Ph.D. in Biochemistry, Molecular Biology from University College London. He has B.S. in Biochemistry from Imperial College London Ltd. He is Director of Curevo, Inc. from March 2025. He is an experienced infectious disease investor. He, serves as Co-Founder & Partner at Medicxi Ventures (UK) LLP from 2023. He served as the Partner of Medicxi Ventures from October 2018 until 2023. He is Director at NovellusDx, Ltd. (also known as FORE Biotherapeutics) since August 2023. He serves on the boards of a number of portfolio companies, including Vicebio Ltd, Vaderis AG and Ateda Therapeutics Limited. He serves as Director of Aura Biosciences, Inc. since April 2019. He serves as a Director at Kurome Therapeutics, Inc. He served as a Principal of Medicxi Ventures February 2016 to September 2018. He was a Principal and Associate at Index Ventures since 2012. He joined Index Ventures in 2012 and was part of the life sciences team. He focused on antibodies, drug discovery and small molecule drugs. He has also delivered competitive intelligence projects for biopharmaceutical companies in the oncology field. During his undergraduate studies, he spent a year working in the Biochemical Pharmacology Group at Serono assessing drug discovery technologies. He is a Director of Aura Biosciences, Inc. He serves as a Director of Gadeta B.V., AbTco, Janpix Ltd. and Encare. He serves as a Director of SuperX Pharma and Kymo Therapeutics. He serves as the Board of Directors of FORE Biotherapeutics’. He has been a Member of supervisory Board of Gadeta B.V. since March 2016. At the LRI, he conducted research focused on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects to biopharmaceutical companies in the oncology field. He performed his Ph.D. research at Cancer Research UK’s London Research Institute. His doctoral work focused on Vascular Biology and Angiogenesis. He obtained BSc in Biochemistry from Imperial College London and PhD in Biochemistry and Molecular Biology from University College London.

Positions